{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:05:03Z","timestamp":1784847903708,"version":"3.55.0"},"reference-count":39,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Established treatments for granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) include the use of immunosuppressive agents for remission induction followed by maintenance therapy. However, patients continue to experience disease progression, organ damage, and adverse events related to current therapies. Avacopan, an oral selective C5a receptor antagonist, was approved by the European Commission in January 2022 for the treatment of adult patients with severe, active GPA or MPA in combination with rituximab (RTX) or cyclophosphamide (CYC). In the pivotal phase 3 ADVOCATE (Avacopan Development in Vasculitis to Obtain Corticosteroid Elimination and Therapeutic Efficacy) study, avacopan was noninferior to prednisone taper in achieving remission at week 26 and superior in sustaining remission at week 52; furthermore, a greater improvement in estimated glomerular filtration rate with avacopan was also observed at week 52. The AvacoStar study will generate data on the benefit and risk and safety profile of avacopan in patients in a real-world context, including in those where treatment may potentially continue beyond 1 year.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The primary objective of AvacoStar is to evaluate the incidence of defined medical events of special interest in patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis commencing avacopan. These include liver injury, cardiac safety, serious infections, and malignancy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n AvacoStar is a noninterventional, multinational, prospective postauthorization safety study. It will enroll up to 500 patients in Germany and the United Kingdom in 2 groups of approximately 250 participants each: those treated with avacopan (plus a standard of care at local investigators\u2019 discretion; usually an RTX- or CYC-based regimen) and a second cohort treated with a CYC- or RTX-based induction regimen without avacopan. Avacopan and the standard of care will be prescribed in the usual manner in accordance with the corresponding summary of product characteristics under the sole decision of the investigator. The treatment decision will fall within current established practice. Eligible participants will be aged \u226518 years with severe, active GPA or MPA as determined by the investigator at the time of commencing avacopan or non-avacopan standard-of-care induction therapy. Patients will be followed for up to 7 years.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study has been enrolling patients since September 11, 2023. The final report is expected in the second half of 2031; interim reports are planned every 24 months after the first patient first visit.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The AvacoStar study will be the largest European prospective real-world evidence comparative study conducted to date that evaluates the long-term safety of avacopan in severe, active GPA or MPA. This study is expected to yield important insights on the use of avacopan in severe, active GPA or MPA in a real-world setting.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/81415","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T17:00:09Z","timestamp":1769619609000},"page":"e81415-e81415","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the Long-Term Safety of Avacopan in Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis in the Real World (AvacoStar): Protocol for a Noninterventional Prospective Cohort Study"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David R W","family":"Jayne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4446-5841","authenticated-orcid":false,"given":"Raashid","family":"Luqmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-7336","authenticated-orcid":false,"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0469-7764","authenticated-orcid":false,"given":"Achim","family":"Obergfell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9672-7281","authenticated-orcid":false,"given":"Charlotte","family":"Pollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9009-8131","authenticated-orcid":false,"given":"Marie","family":"Boff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2924-7333","authenticated-orcid":false,"given":"Monica","family":"Balcells-Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-1801","authenticated-orcid":false,"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"9","key":"R1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092573","article-title":"Systematic review and metaanalysis of worldwide incidence and prevalence of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis","volume":"11","author":"Redondo-Rodriguez","journal-title":"J Clin Med"},{"issue":"19","key":"R2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197319","article-title":"Immunopathogenesis of ANCA-associated vasculitis","volume":"21","author":"Kronbichler","journal-title":"Int J Mol Sci"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m421","article-title":"Management of ANCA associated vasculitis","volume":"368","author":"Wallace","journal-title":"BMJ"},{"issue":"7","key":"R4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/ndt\/gfac320","article-title":"Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis","volume":"38","author":"S\u00e1nchez \u00c1lamo","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"R5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"R6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/ndt\/gfae018","article-title":"Long-term outcome of kidney function in patients with ANCA-associated vasculitis","volume":"39","author":"Sachez-Alamo","journal-title":"Nephrol Dial Transplant"},{"issue":"10427","key":"R7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","journal-title":"Lancet"},{"issue":"3","key":"R8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11739-020-02431-y","article-title":"Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases","volume":"16","author":"Quartuccio","journal-title":"Intern Emerg Med"},{"issue":"8","key":"R9","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"R10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","journal-title":"Ann Rheum Dis"},{"issue":"3S","key":"R11","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group","journal-title":"Kidney Int"},{"issue":"3","key":"R12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.kint.2023.10.009","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the management of ANCA-associated vasculitis","volume":"105","author":"Floege","journal-title":"Kidney Int"},{"issue":"Suppl 3","key":"R13","doi-asserted-by":"publisher","first-page":"iii74","DOI":"10.1093\/rheumatology\/kez618","article-title":"Complications of therapy for ANCA-associated vasculitis","volume":"59","author":"Smith","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"R14","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab018","article-title":"Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic review and meta-analysis","volume":"5","author":"King","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"R15","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1007\/s40620-023-01614-y","article-title":"Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan","volume":"36","author":"Alvarez","journal-title":"J Nephrol"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003956","article-title":"Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis","volume":"10","author":"Scherbacher","journal-title":"RMD Open"},{"issue":"7","key":"R17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","journal-title":"N Engl J Med"},{"issue":"21","key":"R18","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","journal-title":"JAMA"},{"issue":"4","key":"R19","doi-asserted-by":"publisher","DOI":"10.2196\/16664","article-title":"Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide\/azathioprine: protocol for a randomized, double-blind, active-controlled, phase 3 trial","volume":"9","author":"Merkel","journal-title":"JMIR Res Protoc"},{"key":"R20","unstructured":"Tavneos. European Medicines Agency. URL: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tavneos [Accessed 28-02-2026]"},{"issue":"9","key":"R21","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"R22","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70001","article-title":"Safety of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: combined data from three clinical trials","volume":"7","author":"Merkel","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"R23","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi","journal-title":"Kidney Int Rep"},{"issue":"9","key":"R24","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.ekir.2024.07.007","article-title":"Avacopan in anti-neutrophil cytoplasmic autoantibodies-associated vasculitis in a real-world setting","volume":"9","author":"Zimmermann","journal-title":"Kidney Int Rep"},{"issue":"Supplement_1","key":"R25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae069.1249","article-title":"#2256 Safety and effectiveness of avacopan beyond 52 weeks: experience to date in the Early Access Program (EAP)","volume":"39","author":"Alberici","journal-title":"Nephrol Dial Transplant"},{"key":"R26","unstructured":"Avacopan Vifor 10 mg hard capsules. Electronic Medicines Compendium. 2025. URL: https:\/\/www.medicines.org.uk\/emc\/product\/13744\/smpc#gref [Accessed 28-02-2026]"},{"issue":"3","key":"R27","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamadermatol.2016.4920","article-title":"Incidence of and risk factors for skin cancer in organ transplant recipients in the United States","volume":"153","author":"Garrett","journal-title":"JAMA Dermatol"},{"key":"R28","unstructured":"Guidelines for Good Pharmacoepidemiology Practices (GPP). International Society for Pharmacoepidemiology. 2015. URL: https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/ [Accessed 05-02-2026]"},{"key":"R29","unstructured":"Guideline on good pharmacovigilance practices (GVP): module VI \u2013 collection, management and submission of reports of suspected adverse reactions to medicinal products (rev 2). European Medicines Agency. 2017. URL: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf [Accessed 05-02-2026]"},{"key":"R30","unstructured":"Guideline on good pharmacovigilance practices (GVP): module VIII \u2013 post-authorisation safety studies (rev 3). European Medicines Agency. 2017. URL: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf [Accessed 05-02-2026]"},{"key":"R31","unstructured":"Guide on methodological standards in pharmacoepidemiology (revision 11). The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). 2010. URL: https:\/\/encepp.europa.eu\/document\/download\/f6e403a6-8033-4c22-a5ff-195ba3666299_en?filename=01.ENCePPMethodsGuideRev.11.pdf [Accessed 01-03-2026]"},{"key":"R32","unstructured":"ENCePP checklist for study protocols. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. URL: https:\/\/encepp.europa.eu\/encepp-toolkit\/encepp-checklist-study-protocols_en [Accessed 05-02-2026]"},{"key":"R33","unstructured":"Clinical data management. Merative. URL: https:\/\/www.merative.com\/clinical-development [Accessed 05-02-2026]"},{"key":"R34","unstructured":"ICH harmonised guideline: guideline for good clinical practice E6(R3). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 2025. URL: https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf [Accessed 05-02-2026]"},{"issue":"1","key":"R35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/annrheumdis-2012-202750","article-title":"The characterisation and determinants of quality of life in ANCA associated vasculitis","volume":"73","author":"Basu","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"R36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","journal-title":"N Engl J Med"},{"issue":"5","key":"R37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","journal-title":"N Engl J Med"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.631055","article-title":"New insights into novel therapeutic targets in ANCA-associated vasculitis","volume":"12","author":"Nozaki","journal-title":"Front Immunol"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","journal-title":"Semin Arthritis Rheum"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e81415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:15:12Z","timestamp":1782843312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e81415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":39,"URL":"https:\/\/doi.org\/10.2196\/81415","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"article-number":"v15i9e81415"}}